Bioscience Companies
located on the campus of HudsonAlpha

2020
It’s really easy and it’s encouraged to go around, talk to your fellow scientist neighbors, and really get help or anything that you need from the other people that work here. It’s really nice to work in a place where everybody is friendly and we work as a team.

- Sara Cooper, PhD
  Faculty Investigator

If you want to be entrepreneurial, if you want to start companies, if you really want to grow technologies, this is the right field for that. Jim Hudson has done a fantastic job of creating that kind of environment. I didn’t realize how unique it was until looking back to when it wasn’t there, before HudsonAlpha.

- Troy Moore
  Chief Scientific Officer, Kailos Genetics

An opportunity to be with other scientists and other companies and other entrepreneurs was something we couldn’t pass up. It has just been a great opportunity for us as we grow to learn from others. As we say, ‘As the tide rises, all the ships rise with it.’

- Marshall Schreeder
  Executive Vice President, Corporate Development, Discovery Life Sciences
How This Book Works:

The companies located on the HudsonAlpha Institute for Biotechnology campus can be divided into four sub-sectors of life sciences: Research, Testing, & Medical Labs/Clinics; Medical Devices & Equipment; Drugs & Pharmaceuticals; and Bioscience-related Distribution.

Companies are listed below according to their sub-sector. Throughout the book, companies are listed in alphabetical order and categorized by an icon located on the top corner of each page.

**Research, Testing, & Medical Labs/Clinics**

- Acclinate Genetics ........................................ 4
- BioDynami .................................................... 6
- ImIDomics .................................................... 17
- iRepertoire, Inc. ............................................ 18
- iXpress Genes .............................................. 20
- Kailos Genetics ............................................. 22
- Prozone Water Products, Inc. .................... 29
- Smith Family Clinic ..................................... 32
- Sulfilatec ...................................................... 34
- Trideum Biosciences Corp ...................... 40
- Volatile Analysis Corporation .................. 42

**Drugs, Pharmaceuticals & Nutraceuticals**

- Celsion Corporation ....................................... 7
- Everbloom Health ........................................ 12
- Foresight Biosciences, Inc. ....................... 13
- MVW Nutritionals ......................................... 26
- Serina Therapeutics, Inc. ......................... 31

**Medical Devices & Equipment**

- Alimetrix .................................................... 5
- CFD Research ............................................... 8
- GeneCapture ............................................... 14
- iCubate, Inc. ............................................... 16
- Microarrays, Inc. ......................................... 25
- NUB4U ...................................................... 28
- SustainSpace ............................................... 35
- SynVivo ...................................................... 36

**Bioscience-related Distribution**

- Diatherix Eurofins ...................................... 10
- Discovery Life Sciences ............................. 11
- HudsonAlpha Health Alliance .................... 15
- Leavendary .................................................. 24
- Stochos ....................................................... 33
- Theos Health ................................................. 37
- transOMIC Technologies .......................... 39
- Ubiquity Genomics ...................................... 41

**Services**

- DC Box .......................................................... 9
- ITSC Security Solutions ............................. 19
- Jackson Center ............................................ 21
- Keysys .......................................................... 23
- NSS ............................................................ 27
- PTen ........................................................... 30
- The Written Science .................................. 38

To join, contact: Amy Sturdivant  asturdivant@hudsonalpha.org  256.327.9591
Our mission is to achieve health equity and personalized healthcare for all by diversifying genomic data and precision medicine research.

Diversifying genomic research and clinical trials to include more people of color increases knowledge about health issues and makes a difference in personalized healthcare for all. Through our relational network and unique management system, we help bio-pharmaceutical companies and contract research organizations achieve the most representative research sample by expanding their genomic studies and clinical trials to include diverse ethnic groups.

**We Aim to:**
- Improve the completeness and quality of demographic subgroup data collection, reporting and analysis
- Identify barriers to subgroup enrollment in clinical trials and employ contextually relevant strategies to encourage greater participation
- Make demographic subgroup data more available and transparent

**CONTACT**
256.435.2800
www.acclinategenetics.com
www.linkedin.com/company/14866756/admin
www.youtube.com/channel/UCtW5amzLTcGQDzKA0XvHslA
@acclinategenetics

**LEADERSHIP**
Del Smith, PhD
President, Co-Founder
**Alimetrix provides Relevant Diagnostics Empowering Actionable Therapy®**

**Alimetrix** is a CLIA and CAP accredited molecular diagnostic company whose mission is to alleviate patient suffering through the development of state of the art diagnostic tools. Utilizing unique disease insight, coupled with proprietary technologies, Alimetrix is able to provide exceptionally accurate, actionable test results in a timely manner. Being armed with finely detailed and accurate information allows clinicians to gain a clear understanding of the therapeutic needs of the patient. As part of our clinician partnership we seek to provide best-in-class diagnostic assays, helping to facilitate better patient outcomes and actively reduce patient suffering.

**LEADERSHIP**

**Joel Peek, PhD**  
Chief Executive Officer,  
President & Founder

**Mark McQuain, MS, PhD**  
Chief Technical Officer

**Carol Quinter, MSC, PhD**  
Laboratory Director of Clinical Services

**Samantha Bond, MS**  
Director of Microbiology

**Jonas Boateng, PhD**  
Director of Next-Generation Sequencing (NGS)

**Richard Spera, MD, FACP**  
Medical Director

**CONTACT**  
www.alimetrix.com  
844.443.6663  
info@alimetrix.com
BioDynami Corporation is a biotechnology company that provides innovative solutions for life sciences research and development. Currently, BioDynami is focusing on next generation sequencing (NGS) and molecular cloning. We provide reagents for NGS, DNA cloning, and PCR cloning. We also offer services for NGS library construction, custom vector design, and DNA cloning. Our goal is to provide the best solutions in the field to make Research and Development life easier.

**Next Generation Sequencing**
- Quick and efficient DNA library prep reagents for diverse needs
- Library quantification reagents
- NGS services

**Molecular Cloning**
- Effective and simple cloning kits for any type of DNA fragments
- Cloning vectors for common DNA cloning and large DNA cloning
- Cloning services

**DNA Ladders**
- Ready-to-load DNA ladders: cover from 20 bp to 20 kb with easy identification band

**Services**
- **Next Generation Sequencing**: DNA library prep, sequencing
- **Cloning**: any type of DNA fragment cloning; vector design and construction

**CONTACT**
www.biodynami.com  
256.872.0805  
support@biodynami.com

**LEADERSHIP**
Lisa Chen, MBA  
Chief Executive Officer, Co-Founder

Jun Song, MD, PhD  
Chief Technology Officer
**Technology**

**LTSL**, which stands for lysolipid thermally sensitive liposomes, is a unique liposomal technology used in Celsion’s lead product, ThermoDox®. LTSL allows for the triggered release of a drug payload through low temperature (just above body temperature) heat activation. LTSL is a proprietary heat-activated liposomal encapsulation of doxorubicin, which is currently in Phase III development for the treatment of primary liver cancer.

**TheraPlas™** is a versatile technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutic via synthetic non-viral carriers and is uniquely capable of providing cell transfection capability for double-stranded DNA plasmids and large therapeutic RNA segments such as mRNA.

**TheraSilence™** is a versatile technology platform focused on delivering synthetically generated small inhibitory RNAs (siRNAs), microRNAs, microRNA mimics, and related molecules that can regulate protein expression by exploiting endogenous cell mechanisms.

**Product Pipeline**

Celsion’s pipeline includes two clinical-stage candidates targeting various oncology indications and two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA/RNA therapies. These include:

**ThermoDox®** is a proprietary heat-activated liposomal encapsulation of doxorubicin. Celsion is currently enrolling a 550 patient Phase III pivotal study of ThermoDox® in combination with radiofrequency ablation in primary liver cancer. ThermoDox® is also being evaluated in two Phase II studies in recurrent chest wall breast cancer in the U.S. and Europe.

**GEN-1 for Ovarian and Brain Cancers** – Positive safety and encouraging Phase I results with GEN-1 given as monotherapy in patients with peritoneally metastasized ovarian cancer. A Phase Ib trial of GEN-1 in combination with PEGylated doxorubicin in patient with platinum-resistant ovarian cancer has completed enrollment. The Company plans to initiate additional clinical studies with GEN-1 as part of a first line treatment for ovarian cancer as well as a combination treatment for platinum resistant ovarian cancer. GEN-1 has also demonstrated encouraging preclinical activity in glioblastoma multiforme (brain cancer).
CFD Research’s mission is to develop and commercialize innovative technologies. Most of the company’s work is performed through highly competitive research contracts from government agencies. Three core focus areas are aerospace & defense, biomedical & life sciences, and energy & materials.

Bio and Energy Technologies

25 patents in the following key areas:

- Microfluidics – miniaturized sample preparation and manipulation including cell-based assays; leading product technology is SynVivo.
- Electrochemical Devices – Variety of power sources including biologically inspired prototypes; leading product technology is Bio-Battery.
- Chem/Bio Sensors – Optical and electrical sensors for detection of chemical and biological agents.
- Advanced Software Tools – Custom software tools for design analysis of material, devices, and systems.

Testing

SynVivo is currently being tested by a number of academic collaborators, small biotechs and pharma.

Bio-Battery is receiving application development funding from a defense contractor.

Products

SynVivo: Realistic, dynamic, cell-based assays enabling accurate studies of cellular behavior, drug delivery and accelerating drug development cycles.

Bio-Battery: Biologically inspired power sources utilizing enzymes as catalysts to convert readily available fuels such as sugar and alcohol directly into electrical energy.
At **DC BLOX**, we understand that businesses are facing increasing challenges that will have a profound impact on their ability to compete and grow in their markets.

**Key business challenges include:**
Digital transformation is changing the way businesses operate and deliver services. It requires the ability to connect customers to infrastructure in their markets and across the globe. The paradigms of IT infrastructure are radically shifting. The cloud, SaaS, and virtualization require businesses to increase their agility to quickly move from the old way of doing business to the new. New physical and network infrastructure is needed, and businesses must work with state and local governments to build that infrastructure and to develop the workforce and culture to grow their tech economies. DC BLOX exists to provide foundational infrastructure for the digital economy. Our focus is on serving growing markets where availability of secure, reliable multi-tenant data centers is limited.

**We serve local markets by:**
- Meeting business’s local and regional data center needs with Tier 3-rated facilities that provide the security, reliability, cost-efficiency and expertise that allows them to focus resources strategically.
- Connecting businesses to any destination worldwide through our private network and global ecosystem of communications partners. With a software-defined network fabric, connectivity to the cloud, to partners, and to providers is provisioned quickly, enabling fast response to business opportunities.
- Enabling the local communities where we do business. That means investing capital for data center construction and offering resources, services and facilities to local organizations, enhancing our communities through training, collaboration and education.

**LEADERSHIP**
- **Jeff Uphues**
  Chief Executive Officer
- **Mark Masi**
  Chief Operating Officer
- **Chris Gatch**
  Chief Technology Officer

**CONTACT**
[www.dcblox.com](http://www.dcblox.com)
Follow us at Twitter: [@DCBLOXinc](http://Twitter: @DCBLOXinc)
Diatherix Eurofins is an innovative laboratory providing accurate and actionable results in one day for infectious diseases utilizing molecular technologies, including proprietary TEM-PCR™.

**Diatherix Eurofins Distinctions:**
- Delivers one-day results
- Identifies bacteria regardless of recent antibiotic use
- Offers simplicity of single-sample collection
- Identifies difficult to culture pathogens
- Yields a higher level of analytical sensitivity and specificity

**Diatherix Eurofins Benefits:**
TEM-PCR technology is a proprietary, multiplex amplification platform designed to overcome the challenges that exist with conventional laboratory methods and real-time PCR applications.

Improved speed and accuracy of laboratory results lead to:
- Reduced antibiotic utilization
- Improved patient outcomes
- Cost reduction and avoidance
- Increased patient satisfaction
- Greater clinical value

**CONTACT**

www.diatherix.com
866.979.4242

Follow us at
@DiatherixLabs

**LEADERSHIP**

Jennifer Cart
President

Randy Ward, MT (ASCP)
Chief Operations Officer

Stanley Lu
Chief Information Officer

Traci Tyree
Chief Financial Officer

Jeff Wisotskey
Vice President of Operations, Clinical Laboratory Director
Discovery Life Sciences provides biospecimens and ancillary services to researchers focused on oncology, hematology and immunology research. In 2013, Discovery Life Sciences expanded services to include neurology, endocrinology and pulmonology. Discovery Life Sciences provides primary tissues and cells matched with the clinical information scientists need to better validate their research so new drugs can reach the patient bedside more quickly. Most projects are prospective in nature; Discovery Life Sciences collects and processes specimens that meet each researcher’s specific criteria for patient selection and sample preparation. Discovery Life Sciences also continues to expand its ability to source normal biospecimens to support general immunology research. Discovery Life Sciences is currently involved in more than 160 active preclinical or clinical studies with scientists in the U.S., Europe and Asia. Examples of past research include:

Non-small Cell Lung Cancer
Longitudinal collection of blood, sputum and tumor tissue helped develop companion diagnostic for EGFR targeted therapy in Phase I trials. Proved that diagnostic assay is possible on less invasive specimens (blood/sputum).

Glioblastoma Multiforme, Hepatocellular Carcinoma, Breast Cancer (triple negative), Colorectal Cancer
Collection of blood and tumor tissue to identify additional disease indications for lung cancer drug in a Phase III trial.

Breast Cancer, Renal Cell Carcinoma
Collection of tissue and treatment outcome information to validate prognostic test that identifies Herceptin and Sutent responders/non-responders for breast cancer and renal cell carcinoma, respectively.

Mesothelioma
Collection of blood and tumor tissue to validate PI3 kinase biomarker for novel therapeutic compound. Results were extremely promising and researcher plans to push drug from Phase I to Phase III trial because of unmet medical need.

CONTACT
www.dls.com
866.838.2798
info@dls.com

Follow us at Twitter: @DiscLS
Facebook: www.facebook.com/DLSciences

HUNTSVILLE LEADERSHIP TEAM
Marshall Schreeder, Jr.
Executive VP, Corp. Dev.
Luke Doiron
Executive VP, Bus. Dev/Marketing
Jay Scherer
Sr. VP, Blood Products & Services

Will Taylor
VP, Finance and Accounting
Erika Hailes
Director, Quality & Regulatory
Carolyn Dodson
Director, Human Resources
Everbloom Health is a subsidiary of Sufilatex. Everbloom Health, Inc. is dedicated to helping people and patients live well, especially people living with kidney disease. Recognizing the personal challenges that can accompany a renal diet, the company has launched a new kidney-friendly food product to help patients follow their recommended diet.

**Deliciously Innovative**
Everbloom Health, Inc. is dedicated to helping people and patients live well, especially people living with kidney disease. Recognizing the personal challenges that can accompany a renal diet, the company has launched a new kidney-friendly food product to help patients follow their recommended diet.

**Product:**
The company has developed and launched Burl Barley Granola™, a granola product that uses rolled barley as the sole grain source. Barley is a recommended grain for renal diets, due to its lower phosphorous content relative to other grains such as oats. Additionally, clinical research has shown that barley can improve cardiovascular disease risk and may assist in glucose regulation. From a consumer standpoint, barley is largely absent from a western-type diet and few barley-based products are commercially available. Through Burl Barley Granola™, Everbloom Health hopes to help many individuals eat healthier today as a step towards living healthier tomorrow.

**CONTACT**
visit us
www.everbloomlifestyle.com
www.burlgranola.com

256.327.9731

**LEADERSHIP**
Chris Cummings, PhD
CEO

Pinterest: pinterest.com/everbloomlifestyle/
Instagram: BurlBarleyGranola

Ecommerce retail offering Burl Barley Granola™, a kidney-friendly food product
Foresight Biosciences commercializes technology for glycobiology research with an emphasis on creating tools for engineering glycoconjugates that alter the biodistribution of administered therapeutics.

**Technology**

Most FDA approved protein therapeutics are glycosylated. Natural protein glycoconjugates have very specific structures that affect their function and distribution. Therapeutic proteins derived from nonhuman cells often exhibit improper glycosylation that require modification prior to administration.

The company’s technology facilitates protein posttranslational modification, glycoconjugation, and glycan analysis.

**Product & Service**

The company offers benchtop assays for glycoprotein terminal fingerprint analysis, recombinant enzymes, and convenient kits for identifying, repairing and modifying protein glycosylation.

**CONTACT**

www.foresight-bio.com
256.327.9404
rhughes@foresight-bio.com

Follow us at @foresightbio

**LEADERSHIP**

Ronny Hughes, PhD
President

Ernest Curto, PhD
Senior Scientist
The HudsonAlpha Health Alliance is an independent, nonprofit organization designed to help groups and their members get answers that will provide ways to decrease healthcare costs and improve health outcomes. For the past decade our scientists, geneticists and physicians have been applying the power of genomics to make research and medical advances in disease and improve the human condition around the globe. By integrating our expertise in genomics, patient engagement and education, as well as clinical decision support, the HudsonAlpha Health Alliance works to develop customized genomic health screening programs for their patient or employee populations.

These fully customizable patient programs can receive genetic testing for:

- Hereditary cancer risk
- Hereditary cardiac risk
- Rare disease risk
- Medication response

The mission of the HudsonAlpha Health Alliance is to serve as a resource for hospitals, employers and communities to offer customized genomic programs and providing relevant educational information about the appropriate use of genomic services.

LEADERSHIP

Devin Absher, PhD
Director for Genomic Medicine at HudsonAlpha Institute for Biotechnology

Jessica Merritt
Business Development

Contact us to customize a program for your group.

CONTACT

888.528.3694
HAHealthAlliance.org
info@hahealthalliance.org
Follow us at hudsonalpha.org/Alliance
An Opportunity to Revolutionize Point-of-Care Decision Making

Infection diagnosis currently takes 1-3 days to detect. With the ever-increasing number of super bugs and new pathogens infecting humans and animals worldwide, there is an urgent need for a portable, on-site rapid diagnostic that also reports antibiotic resistance/sensitivities.

**GeneCapture** has validated its proprietary breakthrough solution: CAPTURE™ technology to solve this pressing need and developed a portable medical device to rapidly identify pathogens causing infections in humans. Currently functioning in an automated prototype, with results in an hour, the system identifies highly specific pathogenic DNA/RNA signatures using an inexpensive disposable plastic cartridge. This rapid genetic matching technique has many applications in healthcare, environmental testing, food safety, and bio-warfare identification.

Our mission is to bring ‘infection detection’ out of the lab and directly to the patient location whether that’s at a doctor’s office, an airport, a cruise ship, or a battlefield.

**LEADERSHIP**

Peggy Sammon  
Chief Executive Officer, Founder  
Krishnan Chittur, PhD, CTO  
Chief Technology Officer, Founder  
Greg Thompson  
Chief Operating Officer  
Paula Koelle  
Chief Scientist  
Valentine Korman, PhD  
Advisor

**CONTACT**

[www.genecapture.com](http://www.genecapture.com)  
256.783.4506  
psammon@genecapture.com  
Follow us at  
@GeneCapture
iCubate® provides rapid, accurate and affordable syndromic assays to laboratories of all sizes to ensure that healthcare providers have reliable test results for appropriate early treatment to improve patient care and outcomes. Actionable results can shorten hospital stays and reduce institutional costs.

Technology and Product

iCubate’s portfolio of products use proprietary core technology, arm-PCR, which was developed by company founder, Dr. Jian Han. This technology identifies 30 genes in one assay as well as multiple drug resistance markers.

Leveraging this technology during product development, iCubate has created a comprehensive molecular solution for the diagnosis of various infectious diseases. The FDA cleared and CE Marked iC-GPC Assay™ and iC-GN Assay™ enable clinical laboratories in the US and Europe the ability to detect the most common bacterial bloodstream pathogens and their major gene resistance markers.

For the diagnosis of bloodstream infection and sepsis, iCubate provides:

- All-In-One Multiplex PCR MDx Platform
- Bloodstream Pathogen and Resistance Marker Detection
- Affordability for the Small and Large Size Laboratory
- Easy to Use, Sample to Answer Testing
- Rapid Testing for Reliable Actionable Results

LEADERSHIP

Jian Han, MD, PhD
Founder, Chairman of the Board

Carter Wells
Chief Executive Officer

CONTACT
www.icubate.com
855.256.3330
customerservice@icubate.com

Follow us at @iCubate on Twitter, Facebook and Linkedin
**IMIDomics** is a unique company tackling Immune-Mediated Inflammatory Diseases (IMIDs). As an innovative leader in discovery and application of biomarkers and new targets to monitor and cure IMIDs, we create value through the combination of the world’s largest IMID biobank, extensive relevant clinical expertise, high-throughput genomic and genetic analysis, and intellectual property.

We are building the world’s most extensive and comprehensive IMIDs database of novel content. Our Focus is on six common IMIDs: Rheumatoid Arthritis (RA), Crohn’s Disease (CD), Ulcerative Colitis (UC), Psoriasis (PS), Psoriatic Arthritis (PA), and Systemic Lupus Erythematosus (SLE).

We apply ultrahigh-throughput genomic analyses to biological materials from the IMID Biobank and we measure genetic and functional genomics on a genome-wide scale. We include among others deep measurements of mRNA, microRNA, and long non-coding RNA transcripts, DNA methylation, Epigenetic markers, and Immune repertoire. We combine results from different types of genomic measurements to increase the power and to identify the contributors to desired phenotypes, drug response, disease activity, disease severity, or disease stratification.

**LEADERSHIP**

Sara Marsal, MD, PhD  
Founder & Chief Medical Officer

Richard M. Myers, PhD  
Founder & Chief Scientific Advisor

Manuel Lopez-Figueroa, PhD  
Chief Operating Advisor

**CONTACT**

www.imidomics.com  
imidomicslab@gmail.com
iRepertoire uses immune repertoire sequencing technology to access the body’s immunological memory, or “logbook” of all past infection and disease. Sequencing the immune repertoire can yield insights into the nature of the body’s immune response to disease and infection. The future market for iRepertoire will be in clinical and research applications that require immune assessment such as drug treatment monitoring, immune monitoring after stem cell transplantation, vaccine studies, and biomarker development.

iRepertoire sells reagent kits and services for immune repertoire amplification of B cell and T cell receptor sequences, which are compatible with downstream Next Generation Sequencing (NGS). iRepertoire has also automated immune repertoire amplification and extraction on their sister company’s iC-processor (iCubate, Inc.).

**Products**

iRepertoire’s reagent systems allow researchers to easily and inexpensively generate their own high-throughput sequencing libraries in the convenience of their laboratory and analyze their data with iRepertoire’s proprietary software pipeline at no additional cost.

**Technology**

iRepertoire’s novel arm-PCR (amplicon) rescued multiplex PCR) is very sensitive, allowing the amplification of an inclusive immune repertoire from a small sample.

**Services**

Sequencing of the entire repertoire for samples is available in addition to iRepertoire’s new service, iPai. In one of the first commercial services of its kind, paired TCR and BCR chains are sequenced from single cells.

**CONTACT**

www.irepertoire.com  
256.327.0948  
info@irepertoire.com  

Follow us at @iRepertoire

**LEADERSHIP**

Jian Han, MD, PhD  
Chief Executive Officer
Secure Solutions is our mission

To provide high-quality support services to the U.S. Government in the disciplines of Engineering, Science, and Technology by providing best-value solutions which will contribute to our national security efforts.

We consistently provide superior acquisition life cycle support services and deliver quality, on-time, and within budget solutions by leveraging our ability to be flexible, agile, and to rapidly respond to our customers’ needs and requirements.

CONTACT

www.bmksecsuresolutions.com/index2.html

Northern Virginia Office:
AFCEA INT’L HEADQUARTERS
BMK Secure Solutions
4400 Fair Lakes Court, Suite 107
Fairfax, VA 22033
703.865.4524

LEADERSHIP

Patricia Kee
President

Ashley Kee
Chief Executive Officer

Judy Haberman
President DOD and Federal Programs
iXpressGenes (iXG) is a bioengineering and synthetic biology company focused on Protein Crystallization Services, Instrumentation and Contract Research.

**Products & Services**

**Instrumentation:** iXpressGenes has developed a novel technique for identifying early indications of protein crystallization. This technique is now considered a best practice. The company has developed instrumentation to optimize this important phase of research and drug discovery.

**Protein Services:** iXG provides contract services and products for proteins and enzymes, from purification to structural determination. The company has exclusive access to microbes from various extreme environments on earth and on the ocean floor. Some of the extracts are producing antimicrobial activity, which has lead to an innovative research contract with the Department of Defense.

**Research:** Scientists at iXG are exploring synthetic biology solutions in the areas of healthcare, environment and defense. Current research is being conducted on crystals grown in microgravity on the International Space Station.

**LEADERSHIP**

Joseph Ng, PhD  
Chief Executive Officer, Founder

**CONTACT**

www.ixpressgenes.com  
256.426.0413  
info@ixpressgenes.com

Follow us at  
@iXpressGenes
Jackson Center is conveniently located in the heart of Cummings Research Park (CRP), the second largest research park in the United States. It’s no coincidence that our conference center is located in one of the world’s leading science and technology business parks.

Just as CRP is a model for transforming research into business success, Jackson Center is a model for the technical sophistication and specialized services of today’s conference centers. Jackson Center works as a “one-stop center” and can handle conference details and all off-site coordination for your meeting and it even features on-site catering.

Jackson Center provides an environment with a level of intimacy that no other meeting facility can provide. We’re dedicated solely to professional meetings, your conference attendees won’t have to mingle with wedding reception guests in the lobby or wade through vacationing guests to get to their meeting. Our size insures that you won’t be overshadowed by “mega conventions” and events. We offer flexible space to accommodate any conference needs and can handle last minute changes. Parking is a pleasure at Jackson Center, where you can pull up next to the entrance without a problem. No parking decks or long walks.

From a technology standpoint, Jackson Center is better equipped than any other facility in the area, with state-of-the-art audiovisual equipment and an IT support staff that ensures everything runs smoothly on the day of your event. Jackson Center can handle the most technically demanding meetings. In addition, our meeting space is specially engineered with appropriate lighting and acoustics, ergonomic chairs and other features.

**CONTACT**

www.jacksoncenter.net
256.327.9695
jjones@jacksoncenter.net

**LEADERSHIP**

Daniel Laboudiere
Director & Chef

Jamie Jones
Director of Sales

Barry Walker
Operations Manager

Melissa Bennett
Sales Executive & Accounting
With a focus in the fast-growing world of next generation sequencing, Kailos Genetics, through its CLIA Services Laboratory, analyzes DNA for “genetic clues” associated with drug response, adverse response and diagnosis of disease. These clues enable physicians to proactively identify responders and non-responders to certain drug therapies, avoid serious adverse drug reactions that are genetically linked, and diagnose inherited and non-inherited diseases.

The CLIA Services Laboratory at Kailos Genetics currently provides drug metabolism/pharmacogenomic testing services for:

1. Drugs and conditions commonly associated with cardiac disease
2. Drugs and conditions common associated with mental health issues
3. Drugs commonly used to treat pain and pain syndromes

Kailos Genetics services all physician specialties and has business-to-business relationships to leverage its TargetRich™ technology in non-physician and research markets.

**Kailos Solutions**

Laboratories can now access reagents and software solutions from Kailos Genetics to develop next generation sequencing assays in their laboratories. The combination of Target Rich reagents and Kailos Blue, a cloud-based analysis and reporting software solution, provides a cost effective and highly scalable platform for next generation sequencing assay development.

**LEADERSHIP**

- **Brian Pollock**
  President & Chief Executive Officer
- **Troy Moore**
  Chief Scientific Officer
- **Randy C. Bachmeyer**
  Chief Technology Officer
- **Cheri Walker**
  Chief Financial Officer

**CONTACT**

- [www.kailosgenetics.com](http://www.kailosgenetics.com)
- 256.327.9800
- Follow us at @KailosGenetics
About KEYSYS:
KEYSYS is a custom software development company headquartered in Birmingham, Alabama. Since 2007, KEYSYS has focused on helping clients succeed and coworkers thrive. Their agile development process is collaborative, supportive, and uniquely tailored for each individual client’s needs. KEYSYS has been a recipient of the Birmingham Business Journal’s Small Business Award as well as one of “Birmingham’s Best Places to Work”.

We build enterprise software solutions for businesses with locally sourced talent in Birmingham and Huntsville, Alabama. Here are some of the solutions to help our clients needs:

APPLICATION DEVELOPMENT
DASHBOARDS & REPORTING
APPLICATION INTEGRATION
CUSTOM WEB DESIGN & DEVELOPMENT
MOBILE APPLICATIONS
DEV OPS CONSULTING

LEADERSHIP
Jim Bob McAllister
Chief Executive Officer

CONTACT
www.keysys.io
205.421.1700
info@KEYSYS.IO

Follow us on
Twitter: @keysys
Facebook: www.facebook.com/keysysconsulting/
Leavendary provides craft brewers customized “big-brewery” biology that fits the craft brewing context. Innovative craft brewers continually produce new recipes that create new and responsive biology requirements for Leavendary. Leavendary ensures brewers have “pitch perfect” yeast, a first-class quality program, and the biology expertise they need to succeed in a highly competitive market.

**Yeast**
- Delivering pitch-able quantities
- Banking services
- Strain selection assistance

**Bio R&D**
- Custom yeast strains
- Consulting services
- Wild yeast “domestication”

**Microbiology**
- Full service testing
- Contaminant ID/remediation
- Drought testing

*Perfect Pitches, Every Time*
*Craft Biologists Serving Craft Brewers*
*Full Service Beer Biology*

**LEADERSHIP**

Peyton McNully  
Founder

Andy Crouse  
Chief Scientific Officer

**CONTACT**

www.leavendary.com  
256.513.6258  
info@leavendary.com

Follow us at  
@leavendary
**Microarrays Inc.** is a technology company that uses precision robotics to manufacture a product called a microarray. Microarrays are orderly arrangements of capture probes usually made of DNA and/or proteins. These probes are able to “capture” biological information, allowing researchers to rapidly sort through complex samples and identify the presence or absence of targets of interest. Within healthcare, everyone from the patient to the providing institution benefits from the use of array-based tools. For the patient, the diagnostic time savings can mean the difference between a positive or negative outcome, especially in regard to infectious diseases.

**Technologies**

The technologies developed at MI span the full spectrum of array production, from early project conception to manufacturing, final quality control and product validation. MI develops all of the motion-control software, printing robotics and microfluidic deposition technologies used by MI to provide high throughput capability to any project.

**Product & Services**

**DNA/protein/antibody arrays:** Array-based tools allow scientists to better understand the fundamental aspects of cellular biology, as well as to explore the underlying aspects of human genetic disease. MI provides full custom service for organizations seeking assay development assistance.

While best known in the industry for microarray production and assay development, MI has expanded to include gene expression laboratory services.

**CONTACT**

www.microarrays.com  
256.327.0544  
info@microarrays.com

**LEADERSHIP**

Joel Peek, PhD  
President & Chief Executive Officer
**MVW Nutritionals** is a privately held company, with the mission of providing leading edge nutritional supplements and vitamins for persons who have cystic fibrosis and other gastrointestinal disorders. Our goal is to deliver exceptional product profiles, coupled with outstanding service. We believe that quality in what we do, at a reasonable price, are important, and we are committed to this mission.

**About the Company**

MVW is pleased to offer multivitamin products developed to address the varying needs of individuals who have CF. Please see the table below. In 2014, MVW Nutritionals introduced the first multivitamin product to address the CF Foundation’s Guidelines for “step increases” in vitamin D, and will introduce additional products and services in 2015 to support the management of serum vitamin D levels. The Company is also in the process of expanding its focus in 2015 to support the nutritional aspects of other gastrointestinal disorders.

**Products and Availability**

Our products are manufactured at certified cGMP facilities to meet the guidelines set out by the FDA. Routine testing occurs and every product receives a Certificate of Analysis (“COA”) upon release by the Quality Assurance team. In addition to making sure that each product meets its label claim when released, products also undergo stability testing to provide the confidence that the levels of vitamins and minerals needed in your care are consistent with the label through product expiration. We believe this is important, as we seek to ensure the highest standard of quality control from our manufacturers for our customers.

Outside the US, MVW Nutritionals supports the CF Community in Canada through Health Canada’s Special Assistance Program; and is working with others on product registration in several countries.

**CONTACT**

[www.mvwnutritionals.com](http://www.mvwnutritionals.com)
855.236.8584
info@mvwnutritionals.com

Follow us at @MVWNutritionals

**LEADERSHIP**

**Mike Walters**  
President

**Suzanne Michel**  
Registered Dietician

**Melanie Vandiver**  
Operations

---

**MVW Nutritionals, Inc.**
About NSS:
NSS is a dedicated fully managed and scalable IT solution provider that helps small to medium size businesses scale on-demand. These fully managed solutions are world-class IT solutions:

VOIP Solutions
From basic PBX connectivity to advanced call routing, NSS offers turn-key, VoIP telephone solutions custom designed for your company’s individual needs, that slash voice costs while simplifying services and improving business productivity.

Data Management
High-speed data networking solutions connect businesses reliably and efficiently. Gigabit switching and Wi-Fi solutions deliver the latest in secure LAN connectivity and network access.

IT Support
From phone system installation to complete network design, NSS offers personable, best-in-class support from a team of highly-trained engineers, available to help support your network and business needs.

CONTACT
www.nss-corp.com
256.464.0857
info@nss-corp.com

LEADERSHIP
Scott Couch and Scott Cechovic
Founders
NUB4U has patented a system for the real time detection and removal of biological contaminate from fluids. We are currently targeting water for agriculture and 3rd world countries.

The modular system can provide both immediate feedback to the user along with remote data storage and is comprised of a configurable Detection Sensor and an associated Cleaning Manifold. The two components can be used together as a system or individually as required. For most water applications, the Detection Sensor would be the preferred application to not impact current infrastructure and can be used to detect multiple types of contaminates.

Unlike other water quality testing devices/processes which require samples to be sent to a lab, the NUB4U Detection Sensor provides instantaneous feedback to the user if contamination is present.

CONTACT
256.508.9298

LEADERSHIP
Peter Blocker
President

Angelo Bocchino
Vice President Marketing
Prozone Water Products Inc., founded by physicist Ron Barnes in 1977, provides unique solutions and leading edge Ozone, Germicidal UV-C, and Advanced Oxidation Process technologies relating to purification processes of fluids, air and surfaces. As a recognized industry leader, Prozone’s Hybrid Cold Plasma and AOP systems deliver sustainable, on-site production of oxidizers and DNA modification without harmful by-products. Designing safe and efficient methods for industrial and commercial water treatment, Prozone has manufactured and supplied over a million purification systems throughout the world for point-of-use drinking water, cistern and well water systems, aquatics systems, plant, fruit, and vegetable processing systems, fisheries, hatcheries, cooling towers, recreational water, waste and sewage water treatment. Through its research, Prozone continues to innovate oxidation systems technology development for International organizations such as United Nations, NASA, Universities, Corporations and the Departments of Agriculture, Defense and the Interior.

Testing
Prozone’s studies and testing focuses on Ozone and Advanced Oxidation Processes as a means of purifying water; as a biocide for Biofilms; and the destruction of harmful microbes like viruses, bacteria, molds and toxic chemicals. Elimination of Legionella, Cryptosporidium, E-coli, Pseudomonas, Staphylococcus, MRSA, C-Diff and other pathogens found in hospitals, cruise ships, recreational facilities, and rehabilitation facilities is a high priority. Prozone’s continuous study of the efficacy of Ozone and AOP technologies on the destruction of biofilms in water supply lines in cooling towers, closed loop bodies of water and throughout buildings are critical to the protection of human health. These studies are being examined to produce sustainable, on-site products that will ensure the safe and cost effective processing of vegetables, fruit, meat and preparation of food, storage, and preservation.

Key Technologies
Prozone Water Products specializes in small to medium sized ozone and hydroxyl producing systems and has ~ 35 US and international patents in the following key areas:

- Ozone Generation using Hybrid Cold Plasma Germicidal VUV – Designed to harness the VUV spectrum of 185nm photochemical production of ozone and 254nm germicidal DNA modification
- Ozone and UV-C Advanced Oxidation Processing (AOP) – Photochemical method in which photons in the UV spectrum convert ozone in the presence of water to Hydroxyl Radicals
- Oxygen Fed Corona Discharge Air Cooled Ceramic Flat Plate Ozone Generators
- Contacting Systems using Bypass Dynamic Venturi Injectors and Serpentine Counter-Flow Structures

CONTACT
www.prozoneint.com
256.539.4570
sales@prozoneint.com

Follow us at
@ProzoneWater

LEADERSHIP
Ron Barnes
Founder & Chief Executive Officer

Cherie Brook
President
About PTEN Foundation:
The PTEN Hamartoma Tumor Syndrome Foundation was founded to find treatments or therapies for PTEN Syndromes by funding research, PHTS program development, supporting patients, and by raising awareness.

What is PTEN Hamartoma Tumor Syndrome?
PTEN Hamartoma Tumor syndrome (PHTS) is a rare genetic condition that causes increased risk for certain cancers, benign growths, and neurodevelopmental conditions.

Our Mission
The PTEN Hamartoma Tumor Syndrome Foundation was founded to find treatments or therapies for PTEN Syndromes by funding research, providing PHTS education, supporting patients, and by raising awareness. PHTS includes Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and Proteus-like syndrome.

Our History
We are a patient run organization founded in Dec 2013 to serve the PHTS community by connecting patients and clinicians to collaborate and work together toward a treatment or cure.

LEADERSHIP
Kristin Anthony
CEO/President

Andrea Beilstein
Project Director

CONTACT
www.ptenfoundation.org
kristin@ptenfoundation.org
256.52.8529
andrea@ptenfoundation.org
831.521.5778
Serina Therapeutics, Inc. is a privately-held pharmaceutical company that is advancing novel therapeutics for Parkinson’s disease, restless leg syndrome, cancer, epilepsy, inflammation and pain using its proprietary, patented polymer technology. The company has created new pharmaceutical candidates using polyoxazoline (POZ) – a safe, water-soluble polymer to which a variety of small molecules, proteins, peptides and DNA can be attached. This attachment confers a unique pharmacokinetic profile that is markedly different from the parent compound. This profile may confer advantages in terms of safety and efficacy. In general, molecules attached to POZ stay in the body for a much longer period of time – and can be precisely tuned to achieve the desired therapeutic profile. In addition to progressing its CNS-focused pipeline, Serina Therapeutics has partnered its technology with two of the top ten pharmaceutical companies worldwide, and is actively seeking new partnerships.

Trials & Testing
Serina Therapeutics has advanced its first proprietary compound, SER-214, into clinical trials in patients with Parkinson’s disease (PD). SER-214 is a once-per-week injectable that provides continuous drug delivery of a potent dopamine agonist known as rotigotine. Continuous dopaminergic stimulation has been a long-sought clinical strategy in patients with PD for decades, and SER-214 is unique in this mode of action. SER-214 should obviate the phasic peak and trough of many oral drugs used to treat PD – thus preventing “wearing off” and onset of dyskinesia. The Phase 1a trial successfully completed in May 2017. Data show that SER-214 is safe and has predictable pharmacokinetic properties. Serina is planning to initiate Phase 2 trials of SER-214 in patients with Parkinson’s disease and moderate to severe Restless Leg Syndrome. For more information on the Phase 1a trial, please visit https://clinicaltrials.gov/show/NCT02579473.

Key Technology
Novel polymer drug delivery platform based on polyoxazoline - POZ. Serina Therapeutics also holds the global exclusive license to metal-catalyzed “click chemistry” for the development of POZ-therapeutics.

LEADERSHIP
Randall W. Moreadith, MD, PhD
President & Chief Executive Officer
Brendan P. Rae, PhD, JD
Chief Business Officer
Tacey X. Viegas, PhD
Chief Operating Officer
Mike D. Bentley, PhD
Chief Scientific Officer
J. Milton Harris, PhD
Chairman

CONTACT
www.serinatherapeutics.com
256.327.0566
info@serinatherapeutics.com
rmoreadith@serinatherapeutics.com
The Smith Family Clinic for Genomic Medicine, powered by HudsonAlpha, Children’s of Alabama, and UAB Medicine, has been established to use the power of genomics to solve undiagnosed and misdiagnosed cases and provide answers to families and physicians.

**Mission and Vision**
The Smith Family Clinic for Genomic Medicine solves diagnostic mysteries and provides long-sought diagnoses to parents and physicians for diseases that may be impossible to diagnose through other means. The clinic’s mission is not only to help find answers, but also to give patients the best clinical care, a positive medical experience and the information to make future health care decisions.

**Some of the more common symptoms seen in patients at The Smith Family Clinic for Genomic Medicine include, but aren’t limited to:**
- Epilepsy
- Cognitive or developmental delay
- Adult-onset neurological disease (neuropathies, dystrophies, myopathies)
- Primary immune disorders
- Congenital heart defects, cardiomyopathies, or arrhythmias
- Other unexplained or unusual disease processes

**LEADERSHIP**
- **David Bick, MD**
  Medical Director
- **Carol Aiken, CMM, CPAR**
  Clinic Operations Administrator
- **Tammy Dennis**
  Clinical Operations Assistant
- **Kelly East, MS, CGC**
  Genetic Counselor Lead
- **Meagan Cochran, MS, CGC**
  Genetic Counselor
- **Whitley Kelley, MS, CGC**
  Genetic Counselor
- **Veronica Greve, MS**
  Genetic Counselor

**CONTACT**
www.smithfamilyclinic.org
256.327.9640
About Stochos Therapeutics:

Stochos Therapeutics is a growth-stage pharmaceutical development company. One of its projects is a multiplex quantitative PCR for gastrointestinal infectious disease diagnostics.

Goal: Stochos Therapeutics is interested in the utility of this technology and the factors influencing its adoption into routine clinical practice.

LEADERSHIP

David McClure
Founder and CEO
Sulfilatec

*Inspired by biology.*
*Motivated by patients. Sulfilatec.*

**Sulfilatec, Inc.** is a biotech company that is dedicated to helping patients with heart and kidney diseases. Heart disease is the leading cause of death, including among patients with kidney disease. Sulfilatec is discovering and developing new therapeutics for these patients.

As a company, we are committed towards leveraging great science to the benefit of patients. Our drug development platform harnesses groundbreaking discoveries regarding the novel biologic activities of bromide that have been published in top-tier scientific journals. Our lead drug candidates are designed to act on key molecular pathways in heart failure, chronic kidney disease, and certain ESRD-associated comorbidities. Every day, we diligently work to translate these discoveries into new treatments for patients and are always open to exploring new collaboration and partnership opportunities.

**LEADERSHIP**

Chris Cummings, PhD  
President & Chief Executive Officer
About Sustain Space:

Orbital Genomics is an endeavor of SustainSpace to advance astroculture via several means. First, we will employ new space approaches to bring in new resources as well as enable faster development.

Second, we are taking a moderately deep, yet broad approach to astroculture: we are attempting to bridge the various silos.

Third, in addition to traditional physical and hardware approaches, we are working on “soft”, information-oriented approaches such as genomics analytics and new business models. Growing plants is not easy. It has taken decades just to get to the point where actual food for astronauts is being grown, and that is just a few leaves of lettuce so far. Safety and reliability are paramount for the International Space Station (ISS), and neither come cheaply, especially in government operations. However, much research has already been done, and many solvable problems have been identified. Further, the field of biotechnology has itself seen great advances, resulting greatly expanded capabilities at lower costs.

Astroculture has a challenging, yet exciting future in the next several years, as past and new efforts begin to bear fruit, so to speak.

<table>
<thead>
<tr>
<th>LEADERSHIP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Ciotola</td>
</tr>
<tr>
<td>Founder</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CONTACT</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="mailto:mark.ciotola@sustainspace.com">mark.ciotola@sustainspace.com</a></td>
</tr>
<tr>
<td><a href="http://www.sustainspace.com">www.sustainspace.com</a></td>
</tr>
</tbody>
</table>
SynVivo is a physiological, cell-based microchip platform that provides a morphologically and biologically realistic microenvironment allowing real-time study of cellular behavior, drug delivery and drug discovery.

Synvivo, LLC was founded in 2014 as a spin-out from CFD Research Corporation (CFDRC) to commercialize with the Synvivo family of cell-based assays. Synvivo, whose name is derived from synthetic in vivo, is a disruptive technology with a goal to revolutionize drug discovery and precision medicine by providing the most realistic and dynamic in vitro platform for cellular behavior and drug response. The two high-tech domains of microfluidics and bioengineering have enabled Synvivo scientists to analyze and visualize how drugs behave in real-time offering a true breakthrough in drug development. Even more importantly, Synvivo is at the forefront of truly personalized, precision medicine with its technology’s ability to show, in real-time, how a patient will respond to different drugs or combination therapies.

CONTACT
www.synvivobio.com
256.384.4726
info@synvivobio.com
Follow us at @SynVivo

LEADERSHIP
Kapil Pant
President & Chief Executive Officer

B. Prabhakar Pandian
Chief Technology Officer

Gwen Fewell
Chief Commercial Officer
About Theos Health:

Theos Health is a healthcare technology and services company that specializes in virtual telehealth visits using a proprietary platform.

Our core services revolve around telemedicine for post-surgical patients to enable real-time connectivity and enhanced patient engagement. We have developed a proprietary telehealth platform designed around a HIPAA compliant, streaming technology, that also incorporates a patient friendly scheduling software.

Our target customers are large scale, independent surgical and oncology practices that wish to offer a high level of customer service and enhance patient connectivity.

CONTACT
www.theoshealth.com

LEADERSHIP
Dr. Sanat Dixit
Founder
The Written Science offers communication services that support the development and commercialization of novel biotechnology. With scientific expertise and specialized communication experience, The Written Science collaborates with biotechs to clearly convey the commercial value of scientific discoveries to clinicians, investors, users, and consumers.

**Fueling Progress through Partnership:**
The Written Science partners with biotechs to improve the market acceptance of novel biotechnology. Biotechs work with The Written Science to identify and communicate the value proposition of new technology through marketing- and funding-related content. With The Written Science as a partner, biotechs receive the scientific expertise and specialized communication support they need, when they need it.

**Improving Science through Connectivity**
The Written Science translates research into medicine by connecting scientists with perspectives and audiences that improve the relevance and adaptability of novel biotechnology.

**Tailored Services**
The Written Science offers a variety of marketing- and funding-related services, including assistance with:

- Corporate Messaging
- Web Content
- Sell Sheets
- eBooks
- Market Assessments
- Investor Pitch Decks
- Technology Teasers
- Value Propositions
- SBIR/STTR Proposals

**Uniquely Qualified**
The Written Science founder, Rachel Lane PhD, RD, is uniquely equipped to provide communication support to biomedical innovators. Dr. Lane has extensive biomedical research experience that spans biochemistry, molecular biology, aging, nutrition, drug development, and metabolism, and as a dietitian, she worked closely with clinicians to care for patients. Dr. Lane uses this combination of experiences to unify the expertise of scientists, marketing teams, and business leadership so that the clinical significance of novel biotechnology is unmistakable.
At transOMIC Technologies, we believe deeply in the power of science and technology to advance the understanding of biological systems to ultimately improve the quality of life.

Our company provides innovative tools and strategies for life science researchers to help them unravel genetic complexity and to understand disease development. This mission, coupled with a good understanding of the tools that life science researchers need, drives our focus to be a research partner, delivering technologies in a cost-effective and technically supported manner to enable discovery across the genome.

**OUR PORTFOLIO**

**shERWOOD UltramiR Next Generation shRNA Tools for RNA Interference (RNAi)**

RNA interference (RNAi) is a technology used to control the expression of genes by ‘knocking down’ the production of protein that a gene codes for. Like genome-editing tools, RNAi tools are used to create cellular models for understanding our genes and the role they play in disease. Transomic Technologies is the exclusive provider of the next generation of RNAi tools created in collaboration with Cold Spring Harbor Laboratories.

**transEDIT CRISPR-Cas9 Reagents for Genome-editing**

Transomic Technologies has partnered with Dr. Greg Hannon and Dr. Simon Knott of Cold Spring Harbor Laboratories to provide a powerful and extremely versatile set of tools for genome-editing. These tools harness the newly discovered CRISPR-Cas9 technology. Genome-editing allows researchers to ‘edit’ genes in a research setting by changing the sequence of DNA for any given gene. Editing these DNA sequences gives researchers the cellular models needed for understanding disease, which eventually leads to new drugs or therapies.

**Genes for All Species**

Through an arrangement with the National Institutes of Health, Transomic Technologies houses one of the largest repositories of gene content made available to researchers across the globe. This vast collection of genes coupled with our gene-editing tools and RNA interference tools gives researchers a one-stop-shop for planning their gene-centric research experiments.

**CONTACT**

www.transomic.com  
256.327.9510  
info@transomic.com

Follow us at @transOMIC

**LEADERSHIP**

Blake Simmons
Chief Executive Officer
Trideum Biosciences is an award-winning pre-clinical CRO that engages Ph.D. scientists and skilled technical staff to design, troubleshoot, conduct, analyze and report the scientific data. Our customized approach for each client and the insights we provide lead to improved and faster therapeutic, diagnostic and medical device product development.

- Microbiology Testing and Analysis
- Antimicrobial Efficacy Testing
- Biofilm Testing
- Bacteriophage Testing
- Extraction of high-quality genomic material
- Customized testing protocols

Consultation for Scientific Endeavors
We have a proven track record of scientific consultation for various clients.
- Providing a path-forward for product development
- Research Study Design
- Data Review and Reporting
- Scientific Assessment of various products and technologies
- Preparation and Review of scientific documents including grants

Research & Analysis
We conduct precise and thorough GLP-compliant laboratory testing to produce reliable, high quality data. Our expertise in infectious diseases and wound care enable us to effectively assist University and government research as well as domestic and international companies seeking to bring products to the U.S. market.

CONTACT
www.trideumbiosciences.com
256.704.6100
info@trideumbiosciences.com
Follow us at
@Trideum

LEADERSHIP
Van Sullivan
President
Mina Izadjoo, PhD
Chief Science Officer
Ubiquity Genomics provides tools for targeted DNA sequencing. The company’s proprietary technology allows researchers to focus genetic and epigenetic analyses on large regions of the genome at a fraction of the cost of other commercially available approaches. Ubiquity Genomics offers customized sequencing services, as well as pre-made targeting kits. The first pre-made kit is complete MHC, which enables scientists to sequence the entire MHC locus, a region of great importance to immunological disease research. Ubiquity also offers kits for the enrichment of human DNA from contaminated sources, such as saliva. These kits will also deplete human DNA when the research is focused on the microbiome.

CONTACT
www.ubiquitygenomics.com
256.327.9833
info@ubiquitygenomics.com

Follow us at
@UbiquityGenomic

LEADERSHIP
Devin Absher, PhD
Chief Executive Officer
**Volatile Analysis Corporation** (VAC) is a privately held company that specializes in volatile chemical utilization, detection, measurement, and olfaction. Small, volatile (propensity to exist as gas) chemicals are responsible for all aromas/odors, and quite important in biological and industrial applications.

**Technology**

VAC is an analytical problem-solving and consulting company specializing in the detection, identification, and measurement of trace level and ultra-trace level chemicals responsible for odor and aroma. An expert staff utilizes combinations of analytical chemistry and sensory analysis to develop strategies for completely solving or mitigating costly odor problems perceived by consumers as indicative of tainted, potentially dangerous, or just unacceptably poor quality products.

VAC works with industries where aroma/odor is important. Examples include paper and packaging, pharmaceutical, food and beverage, cosmetic, apparel, manufacturing (light and heavy), and automotive. The analytical/sensory division provides deployable aroma/odor analysis and panel training. Sensory trained staff review industrial processes and coordinate odor remediation efforts. Analytical services specializes in quantification of trace level and ultra-trace level (ng/g or parts per trillion and lower) chemicals responsible for odor and aroma.

**Research & Development**

VAC is a research and development company that focuses on volatile chemical applications. Opportunities are numerous and include:

- **metabolomics** (disease diagnosis via trace level volatile chemical biomarkers present in the breath, perspiration, urine of humans and animals)
- **genetic modification impact on the volatile chemical profiles of plants and animals**
- **chemical communication** (identification and measurement of chemicals utilized for biological system communication for example pheromones)
- **olfaction and aroma activity**

Hardware and methods for concentrating and identifying volatile chemicals and their olfaction properties are also active research areas. Patent-pending technology includes devices that enhance chemical detection.

**LEADERSHIP**

**Katherine Bazemore**
President &
Chief Executive Officer

**Matthew Shirley**
Chief Operating Officer

**Russell Bazemore, PhD**
Senior Vice President of Research & Development

**Chris Christianson, PhD**
Senior Vice President, Analytical Services

**CONTACT**

www.volatileanalysis.com
256.486.3531
info@volatileanalysis.com

Follow us at
@VACHuntsville
Southern Living
Huntsville has one of the most favorable salary-to-cost-of-living ratios in the Southeast.

Top 5
Alabama is a nationally recognized workforce recruitment and training program as one of the Top Five workforce training agencies in the United States, according to Area Development, Summer 2015.

8th
Alabama ranks No.8 in the United States for biopharmaceutical job creation, according to Site Selection Magazine and Clustermapping US.

Biosciences are a priority for the city of Huntsville, Madison County, the state of Alabama and many of our regional economic development partners. HudsonAlpha is working with the economic development partners to strengthen policies and incentives for the life sciences industry.

HudsonAlpha is surrounded by a community of talented, skilled and intelligent individuals motivated to apply knowledge in ways that create tangible benefits. Engineering in North Alabama propelled rockets into orbit, landed men on the moon and sent information-seeking probes into deep space. For more than 50 years, Huntsville has applied its expertise to aviation and missiles at the U.S. Army’s Redstone Arsenal, and has accomplished great feats for NASA and the Army. HudsonAlpha is applying the same passion and drive to the promise of genomics and use of biotechnology to improve the way we approach health and disease.

The Huntsville metro area has the highest per capita concentration of engineers and technology workers in the country, and more than half of Huntsville area residents have degrees in engineering and science-related fields.

The colleges and universities in Huntsville and the surrounding areas offer two-year, four-year and advanced degrees in the biosciences and related fields. Alabama is a “right to work” state. The state promotes economic growth by offering customized training and support services for new and expanding businesses.

Biosciences are a priority for the city of Huntsville, Madison County, the state of Alabama and many of our regional economic development partners. HudsonAlpha is working with the economic development partners to strengthen policies and incentives for the life sciences industry.

Informed consumers and communities of genomic information
Career-ready life science researchers and workforce
Genomic Education
Students
Educators
Community
Healthcare Professionals
BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA

Why Locate on HudsonAlpha’s Collaborative Campus?

The primary benefit of establishing a startup, fostering an early stage company, or relocating a mature enterprise to HudsonAlpha is collaboration with leading-edge intellectual talent that provides opportunities for life sciences companies of all stages to grow and expand.

Advantages of Cummings Research Park
The 152-acre HudsonAlpha Institute for Biotechnology campus is located in Cummings Research Park, the second largest research park in the United States. Cummings Research Park co-locates Fortune 500 companies with local and international businesses specializing in a range of high-tech industries: aerospace and defense, hardware and software development, engineering, and research and development. The HudsonAlpha campus is minutes from the Port of Huntsville (Huntsville International Airport and International Intermodal Center) and convenient to Interstate 565, Interstate 65, and the Tennessee River Waterway system.

Grow with Us
Locating on HudsonAlpha’s campus offers any size company access to the cutting edge of biotechnology and flexibility to grow. Superior shared amenities and administrative support, unavailable in conventional office settings, power your progress and provide space for expansion.

“HudsonAlpha coordinates closely with Associate Companies to foster growth and ensure success.”

—Carter Wells
Vice President for Economic Development, HudsonAlpha

HudsonAlpha Campus is part of the
largest research and technology park in the world.

largest research park in the United States and

2nd

4th

44  BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA
Culture of Collaboration
Acquisition, analysis, and application of genomic research happening here inspires innovations in life sciences companies. HudsonAlpha offers turnkey or build-to-suit office/lab space on a state-of-the-art biotech campus with an energizing environment, blending research, education, medicine, and commercialization.

Unrivaled Inspiration & Business Advantages
- Campus address with shared spaces and centralized services including: atrium/cafe, security, meeting spaces, waste management and recycling, and shipping and receiving.
- Labs built to NIH standards for biosafety, with single pass air and emergency power, LEED certified space, and electric vehicle (EV) charging station on campus.
- Administrative services and strategic support: investor forums, job postings, marketing resources, networking, world-class human and plant sequencing and analysis services.
- Fully-managed, on-site IT services with multiple, diverse path ISP up to 200G, customized net topologies, VPNs, phone, and voicemail that provides reliability, control, capacity, and speed.

No.1 for STEM Graduates
“Huntsville is NerdWallet’s second best place for tech jobs in the U.S.”
— Forbes, April 2015

“Huntsville is the #3 city where your money goes the farthest.”
— Boston Business Journal, October 2015

INNOVATE

“The Value of HudsonAlpha to the Alabama Economy $2.45 Billion 2006-2018

$600 Million Up IN THE PAST 24 MONTHS

Huntsville, you can do your research, development, engineering, and manufacturing all in the same location. This systems approach is why Huntsville continues to be on the radar for companies looking to innovate and create.”
— Tommy Battle
Mayor, City of Huntsville

“Huntsville is NerdWallet’s second best place for tech jobs in the U.S.”
— Forbes, April 2015

In Huntsville, you can do your research, development, engineering, and manufacturing all in the same location. This systems approach is why Huntsville continues to be on the radar for companies looking to innovate and create.”
— Tommy Battle
Mayor, City of Huntsville

Unrivaled Inspiration & Business Advantages
- Campus address with shared spaces and centralized services including: atrium/cafe, security, meeting spaces, waste management and recycling, and shipping and receiving.
- Labs built to NIH standards for biosafety, with single pass air and emergency power, LEED certified space, and electric vehicle (EV) charging station on campus.
- Administrative services and strategic support: investor forums, job postings, marketing resources, networking, world-class human and plant sequencing and analysis services.
- Fully-managed, on-site IT services with multiple, diverse path ISP up to 200G, customized net topologies, VPNs, phone, and voicemail that provides reliability, control, capacity, and speed.
Next door to discovery - with space, talent, and bandwidth to grow.

To learn more about the advantages of HudsonAlpha and locating your bioscience company in Huntsville, Alabama, visit hudsonalpha.org/innovate.

601 Genome Way
Huntsville AL 35806
www.hudsonalpha.org

Carter Wells, Vice President for Economic Development
cwells@hudsonalpha.org | 256.327.5241

Amy Sturdivant, Director of Business Recruitment
asturdivant@hudsonalpha.org | 256.327.9591